touchLearning Activities
Education, Conference Coverage and Articles
Extended follow-up from the phase 3 INDIGO trial presented at ASCO 2026 provides further evidence that vorasidenib may offer durable disease control in patients with grade 2 glioma harboring IDH1/2 mutations, reinforcing earlier findings that led to its regulatory approvals. In the article below, we provide a details analysis of the latest INDIGO data and Dr Timothy Cloughesy's expert perspective on what the longer-term efficacy and safety findings could mean for the evolving treatment landscape in IDH-mutant glioma.
Could upfront PARP inhibition transform outcomes for patients with HRR-altered metastatic hormone-sensitive prostate cancer? New data from the landmark TALAPRO-3 trial show meaningful rPFS gains with talazoparib plus enzalutamide, reinforcing the importance of early biomarker testing. [touchplayvideo video_id="m9...
From adjuvant immunotherapy to microbiome-driven precision medicine, the biggest renal cell carcinoma abstracts presented at ASCO 2026 highlight where the field is heading next, and what may change first. In this round-up, we discuss the key data from four of the meeting’s most important studies, from investigational to late-phase: RAMPART, KEYNOTE-564, CaboNivo in patients with nccRCC and microbiome-based predictive biomarker development in mRCC.
Bladder cancer’s treatment landscape is changing fast; and the biggest abstracts presented at ASCO 2026 show just how far that shift now extends. With insight from our Editor-in-Chief, Prof Axel S Merseburger (University Hospital Schleswig-Holstein, Germany), we examine the four studies likely to have the biggest impact on clinical practice across advanced and localized disease: EV-302, KEYNOTE-905, SAKK 06/19 and POTOMAC.
Landmark abstracts across localized and advanced prostate cancer presented at ASCO 2026 addressed treatment intensification, biomarker-driven therapy, radiotherapy modality comparisons, and novel radioligand strategies. In this piece we examine four studies that reflect important shifts in prostate cancer management, influencing both near-term treatment pathways and future: PROTEUS, TALAPRO-3, COMPPARE and ProstACT Global.
Several late-breaking gastrointestinal oncology studies presented at ASCO 2026 highlighted how treatment selection is continuing to evolve across colorectal, hepatobiliary, gastric, and esophageal cancers, with new data on ctDNA-guided adjuvant therapy, earlier integration of targeted agents, and intensified perioperative strategies. In this round-up, we have selected six of the most important late-breakers, and examine the latest data from CIRCULATE, BREAKWATER, EMERALD-3, Neo-CRAG, SCIENCE, and RC48-C027.
New ASCENT-04 data presented at ASCO 2026 suggest that first-line sacituzumab govitecan plus pembrolizumab may provide sustained clinical benefit beyond first progression in patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer. The exploratory post-hoc analysis showed improved PFS2 versus chemotherapy plus pembrolizumab, despite high crossover to sacituzumab govitecan in the control arm.
Dr Rupert Bartsch (University of Vienna, Austria) highlighted six important studies across the breast cancer landscape presented at ASCO 2026. The studies below discuss interesting and strategic developments in genomic risk stratification in early disease, supportive care optimization, HER2-positive metastatic strategies and novel antibody–drug conjugates in triple-negative breast cancer.
At ASCO 2026 several neuro-oncology presentations focused less on introducing entirely new paradigms and more on defining where existing and emerging therapies may best fit. Across brain metastases and glioma, phase 3 data addressed longstanding practical questions around radiation delivery, chemotherapy duration, and local therapies, while updated targeted therapy data in IDH-mutant glioma continued to mature. In this piece, Dr Rimas Lukas highlights four main abstracts from ASCO 2026, discussing their take-aways and considering their potential relevance for clinical practice.
Glioblastoma (GBM) places an enormous emotional and practical burden on both patients and caregivers. At AAN 2026, Dr Jigisha Thakkar et al. explored how cultural and ethnic differences influence preferences for communication and care delivery in neuro-oncology settings. In this Q&A, Dr Thakkar discusses the key takeaways from her study, and how these findings could help shape more individualized approaches to neuro-oncologic care.
At AAN 2026, Dr Jigisha Thakkar presented data challenging long-standing assumptions of continuous tumor growth and suggesting that some patients may benefit from more individualized surveillance and treatment strategies. In this Q&A, Dr Thakkar discusses how intermittent dormancy in IDH-mutant gliomas may influence clinical decision-making, from MRI surveillance intervals to the timing of therapeutic intervention.
ASCO 2026 showed that thoracic oncology is moving beyond promising signals and increasingly closer to practice-changing evidence across multiple fields — from bispecific antibodies and ADC-based combinations to targeted therapy in both metastatic and peri-operative settings. In this piece, Dr Federico Monaca breaks down eight major abstracts from ASCO26, highlighting their take-aways and considering their potential relevance for clinical practice.
The five selected Plenary late-breaking abstracts at the ASCO 2026 Annual Meeting in Chicago showcased some of the meeting’s most practice-influencing data. Across prostate cancer, sarcoma, lung cancer and pancreatic cancer, these phase 3 studies demonstrated meaningful improvements in survival outcomes, highlighting the growing impact of perioperative intensification, precision oncology and novel targeted therapies in difficult-to-treat disease settings.
At the 7th SIOP Europe Annual Meeting, the Projects in Spotlight sessions showcased the collaborative initiatives between SIOP Europe and key stakeholders. From innovation, rare malignancies and psychosocial support to survivorship, these projects aim to improve outcomes, coordination between research and clinical care, reduce inequalities, and strengthen patient-centred care across Europe. Scroll down for a snapshot of each project and click on the headings to find out more.
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical career. Today we explore how to develop the right team around you to support your work, and what building that bench can mean for your career, and the life you build alongside it.
Congress coverage | This May, experts from around the world gathered in Glasgow, Scotland for the the 7th SIOP Europe Annual Meeting. This year celebrated the importance of collaboration, bringing together the diverse stakeholders involved in facing children and adolescents with cancer, and ensuring all voices were heard. The Annual Meeting was held in partnership with CCI Europe, ensuring the representation and participation of childhood cancer parents and survivors.
At the 7th SIOP Europe Annual Meeting, emerging therapies, biological precision, and workforce development are all under the spotlight. Dr Daniela Di Carlo (Chair, Young SIOPE), reflects on where the field is heading, particularly CAR T-cell therapy and artificial intelligence, and what is needed to ensure that progress translates into real-world benefit for children with cancer.
touchONCOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
